Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
$18.17
$18.16
$8.00
$21.70
$1.85B1.45361,806 shsN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$14.97
+1.9%
$13.82
$8.02
$15.78
$7.29B1.675.03 million shs3.76 million shs
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$116.34
+3.3%
$109.31
$95.49
$148.06
$6.82B0.32834,933 shs967,302 shs
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
$44.02
+4.2%
$33.81
$27.34
$60.87
$7.76B0.191.37 million shs1.48 million shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
0.00%0.00%0.00%0.00%0.00%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-0.78%-1.42%+8.92%+64.87%+15.29%
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
-0.19%+1.09%+4.78%+8.97%+3.34%
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
+1.54%+7.07%+24.21%+22.48%-28.11%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.0647 of 5 stars
1.41.00.00.33.41.71.3
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
4.8897 of 5 stars
4.51.00.04.02.83.32.5
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
3.7138 of 5 stars
4.53.00.00.03.41.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
0.00
N/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.88
Moderate Buy$16.007.13% Upside
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
2.93
Moderate Buy$181.6455.80% Upside
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
2.91
Moderate Buy$73.3366.83% Upside

Current Analyst Ratings Breakdown

Latest AKCA, ELAN, JAZZ, and LEGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/22/2025
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$166.00 ➝ $165.00
7/17/2025
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
Johnson Rice
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
7/17/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
7/17/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$18.00
7/17/2025
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00
7/15/2025
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$152.00
7/10/2025
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$80.00 ➝ $81.00
7/8/2025
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00
7/2/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$16.00 ➝ $17.00
7/2/2025
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$60.00 ➝ $54.00
6/26/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
$488.54M3.78$0.51 per share35.54$5.78 per share3.14
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.44B1.67$2.28 per share6.56$12.33 per share1.21
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$4.07B1.73$31.34 per share3.72$67.72 per share1.72
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
$627.24M12.88N/AN/A$5.70 per share7.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
$40.77M$0.48N/AN/AN/A-12.34%-8.94%-8.02%N/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$338M$0.7420.2516.782.888.43%7.54%3.57%8/7/2025 (Estimated)
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$560.12M$7.5015.596.235.6411.86%26.62%9.14%7/30/2025 (Estimated)
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
-$177.03M-$0.59N/AN/AN/A-29.95%-21.19%-13.47%8/8/2025 (Estimated)

Latest AKCA, ELAN, JAZZ, and LEGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/8/2025Q2 2025
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
-$0.18N/AN/AN/A$237.49 millionN/A
8/7/2025Q2 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.1989N/AN/AN/A$1.19 billionN/A
7/30/2025Q2 2025
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
-$5.61N/AN/AN/A$1.05 billionN/A
5/13/2025Q1 2025
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
-$0.40-$0.07+$0.33-$0.27$190.83 million$195.05 million
5/7/2025Q1 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.31$0.37+$0.06$0.14$1.17 billion$1.19 billion
5/6/2025Q1 2025
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$4.65$1.68-$2.97-$1.52$984.16 million$897.84 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
N/AN/AN/AN/AN/A
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
N/A
12.17
11.78
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.68
2.71
1.46
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
1.28
3.38
2.97
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
0.30
5.20
5.07

Institutional Ownership

CompanyInstitutional Ownership
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
19.27%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
89.14%
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
70.89%

Insider Ownership

CompanyInsider Ownership
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
1.50%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.89%
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
4.30%
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
0.02%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
248101.60 millionN/AOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,000496.65 million492.23 millionOptionable
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
2,80060.51 million57.91 millionOptionable
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
2,609183.76 million183.73 millionOptionable

Recent News About These Companies

HC Wainwright Forecasts Legend Biotech Q2 Earnings
Q1 EPS Estimates for Legend Biotech Boosted by HC Wainwright

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Akcea Therapeutics stock logo

Akcea Therapeutics NASDAQ:AKCA

Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$14.96 +0.29 (+1.94%)
Closing price 03:58 PM Eastern
Extended Trading
$14.19 -0.78 (-5.18%)
As of 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Jazz Pharmaceuticals stock logo

Jazz Pharmaceuticals NASDAQ:JAZZ

$116.34 +3.69 (+3.28%)
Closing price 04:00 PM Eastern
Extended Trading
$113.51 -2.83 (-2.43%)
As of 06:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Legend Biotech stock logo

Legend Biotech NASDAQ:LEGN

$44.02 +1.79 (+4.24%)
Closing price 04:00 PM Eastern
Extended Trading
$44.12 +0.09 (+0.22%)
As of 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.